Cash on Hand for DexCom (DXCM)
According to DexCom's latest reported financial statements, the company's latest reported cash and short-term investments is $2.00B USD. Cash on hand here is cash, cash equivalents, and short-term investments reported at the end of each period — the most liquid assets on the balance sheet. Compare with total debt for a net cash/debt picture and with total assets for the share of assets held in cash.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
DXCM
Currently viewingCash on HandSwitch metric
Latest period
$2.00B
YoY change
-22.5%
5Y CAGR
-5.9%
Peak year (2021)
$2.73B
Latest annual
$2.00B
Cash on Hand history chart for DexCom (DXCM) from 2000 to 2025
Cash on Hand history table for DexCom (DXCM) from 2000 to 2025
| Fiscal year | Period ended | Reported | Cash on Hand | YoY |
|---|---|---|---|---|
| 2025 | $2.00B | -22.5% | ||
| 2024 | $2.58B | -5.3% | ||
| 2023 | $2.72B | +10.9% | ||
| 2022 | $2.46B | -10.1% | ||
| 2021 | $2.73B | +0.9% | ||
| 2020 | $2.71B | +76.6% | ||
| 2019 | $1.53B | +10.7% | ||
| 2018 | $1.39B | +152.6% | ||
| 2017 | $548.60M | +343.5% | ||
| 2016 | $123.70M | +7.4% | ||
| 2015 | $115.20M | +37.8% | ||
| 2014 | $83.60M | +53.1% | ||
| 2013 | $54.60M | +12.1% | ||
| 2012 | $48.70M | -40.5% | ||
| 2011 | $81.91M | +73.9% | ||
| 2010 | $47.11M | +68.2% | ||
| 2009 | $28.02M | +3.5% | ||
| 2008 | $27.07M | -57.9% | ||
| 2007 | $64.32M | +18.0% | ||
| 2006 | $54.51M | +7.9% | ||
| 2005 | $50.52M | +85.6% | ||
| 2004 | $27.23M | +36.0% | ||
| 2003 | $20.02M | — | ||
| 2001 | $7.78M | -44.0% | ||
| 2000 | $13.90M | — |
Cash on Hand values are taken from DexCom's reported balance sheets (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
2025's annual cash and short-term investments for DexCom (DXCM) came in at $2.00B – declined 22.5% year-over-year.
DexCom cash and short-term investments compound annual growth for the 2020–2025 (5 years) window is -5.9%, with a net decline across the window.
DexCom cash and short-term investments peaked at $2.73B in 2021; the latest annual figure is $2.00B in 2025 (26.8% below peak).
Across the available history, cash and short-term investments reached its high of $2.73B in 2021 and its low of $7.78M in 2001.
Among 8 Healthcare peers, DexCom (DXCM) ranks 9th; the peer median for cash and short-term investments is $11.85B.
DexCom Cash on Hand by Year
DexCom Cash on Hand 2025: $2.00B
DexCom cash and short-term investments in 2025 was $2.00B, declined 22.5% below 2024.
DexCom Cash on Hand 2024: $2.58B
DexCom cash and short-term investments in 2024 was $2.58B, declined 5.3% below 2023.
DexCom Cash on Hand 2023: $2.72B
DexCom cash and short-term investments in 2023 was $2.72B, grew 10.9% from 2022.
DexCom Cash on Hand 2022: $2.46B
DexCom cash and short-term investments in 2022 was $2.46B, declined 10.1% below 2021.
DexCom Cash on Hand 2021: $2.73B
DexCom cash and short-term investments in 2021 was $2.73B.
See more financial history for DexCom (DXCM).
Sector peers — Cash on Hand
Companies in the same sector as DexCom, ranked by their latest cash and short-term investments.
| Company | Cash on Hand | Sector |
|---|---|---|
| UnitedHealth Group Incorporated (UNH) | $28.12B | Healthcare |
| Novo Nordisk A/S (NVO) | $26.96B | Healthcare |
| Johnson & Johnson (JNJ) | $20.10B | Healthcare |
| Merck & Co., Inc. (MRK) | $14.56B | Healthcare |
| Amgen Inc. (AMGN) | $9.13B | Healthcare |
| Eli Lilly and Company (LLY) | $7.27B | Healthcare |
| AstraZeneca PLC (AZN) | $5.74B | Healthcare |
| AbbVie Inc. (ABBV) | $5.26B | Healthcare |
Frequently asked questions
What is DexCom's cash and short-term investments?
- Latest reported cash and short-term investments for DexCom (DXCM) is $2.00B (period ending December 31, 2025).
How has DexCom cash and short-term investments changed year-over-year?
- DexCom (DXCM) cash and short-term investments changed -22.5% year-over-year on the latest annual filing.
What is the long-term growth rate of DexCom cash and short-term investments?
- DexCom (DXCM) cash and short-term investments compound annual growth rate is -5.9% over the most recent 5 years available.
When did DexCom cash and short-term investments hit its highest annual value?
- DexCom cash and short-term investments reached its highest annual value of $2.73B in 2021.
What was DexCom cash and short-term investments in 2024?
- DexCom (DXCM) cash and short-term investments in 2024 was $2.58B.
What was DexCom cash and short-term investments in 2025?
- DexCom (DXCM) cash and short-term investments in 2025 was $2.00B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
DXCM Overview
Company profile, financial tools, and key metrics
DXCM Revenue Counter
Earns $147.83 every second. See per minute, hour, and day.
DXCM Earnings Counter
Earns $26.52 per second net profit. See per minute, hour, and day.
DXCM Economic Scale
Exceeds Suriname's GDP. Compare with world economies.
DXCM What If Invested
What if you had invested $1,000? See historical returns from any date.
DXCM How It Makes Money
Discover visual breakdown of $4.66B in revenue — where it comes from and where it goes.
DXCM Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
DXCM Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
DXCM Daily Price Character
Explosive · 49.4% historical win rate (green days). Streaks & record days.
DXCM Buybacks
1.95% TTM buyback yield. Shareholder yield & SBC comparison.
DXCM Stock Split History
1 split on record. Dates, ratios, and cumulative multiple.